发明名称 Class I Anti-CEA Antibodies and Uses Thereof
摘要 The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.
申请公布号 US2015111279(A1) 申请公布日期 2015.04.23
申请号 US201414576656 申请日期 2014.12.19
申请人 IMMUNOMEDICS, INC. 发明人 Hansen Hans J.;Chang Chien-Hsing;Goldenberg David M.
分类号 C07K16/30;A61K49/22;C07K14/54;A61K47/48;A61K39/395;A61K51/10;A61K49/00 主分类号 C07K16/30
代理机构 代理人
主权项 1. A chimeric, humanized or human Class I anti-CEA antibody or fragment thereof, wherein the Class I anti-CEA antibody or fragment thereof comprises the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6), wherein the antibody or fragment thereof comprises human antibody IgG4 constant region sequences.
地址 MORRIS PLAINS NJ US